Congressmen Mike Michaud (R-ME), Dan Burton (R-IN) and Tim Ryan (D-OH) wrote House Energy and Commerce calling for a hearing to examine alleged conflicts of interest involving FDA's decision not to approve Provenge. They said “there is reason to believe that serious ethics rules were violated by two FDA advisory panel members.”